Ardea Biosciences — Shareholder Meeting (May 2008)
34 slides from Ardea Biosciences's shareholder meeting presentation, May 23, 2008
Slide 1: 2008 Annual Stockholder Meeting
2008 Annual Stockholder Meeting Barry D. Quart, PharmD President & Chief Executive Officer May 22, 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Investment Highlights
Investment Highlights Five NCEs in clinical trials by end of 2008 Clinical results during 2008: Phase 2a HIV results with RDEA806 Phase 1 inflammatory cytokine lowering with RDEA119 Phase 2 gout results with RDEA806 Phase 1 uric acid lowering with RDEA594 Phase 1 advanced cancer patients with RDEA11
Slide 4: Pipeline Addresses Major Markets
Pipeline Addresses Major Markets RDEA806 RDEA427 RDEA806 RDEA119 RDEA119 RDEA436 Discovery Preclinical Phase 0/1 Phase 2 Phase 3 NNRTI for HIV NNRTI for HIV Gout MEKI for Cancer MEKI for Inflammation MEKI for Cancer/Inflammation 4 Gout RDEA594
Slide 5: HIV Market Opportunity
HIV Market Opportunity Over $8 billion mature market focused on safety and convenience Highest success rate in Phase 3 of any class Three primary classes of therapies: 10 approved protease inhibitors (PIs) 12 nucleosides (NRTIs; single agents and combinations) Only 4 approved non-nucleosides (NNRTIs
Slide 6: RDEA806 vs. Target Product Profile
RDEA806 vs.Target Product Profile Highly active against efavirenz-resistant strains High genetic barrier to resistance Better safety profile than efavirenz (or competitors) Reduced CNS toxicity (no abnormal dreams or significant dizziness) Improved lipid profile (does not increase cholesterol or tri
Slide 7: Phase 2a ART Naive Proof-of-Concept Study
Phase 2a ART Naive Proof-of-Concept Study Study RDEA806-201 ART-Naive Monotherapy Primary Endpoint Change from baseline in plasma VL Secondary Endpoints VL decay rate, CD4 and CD8 changes, PK/PD, safety, tolerability, genotypic and phenotypic resistance Location EU: Moyle (UK), Stoehr (Germany), Rie
Slide 8: Study RDEA806-201: Mean Viral Load Change
Study RDEA806-201: Mean Viral Load Change Preliminary Results Placebo Adjusted Percent < 400 copies RDEA806 400mg BID - 50% RDEA 806 600mg QD - 50% Raltegravir 400mg BID - 50% (Day 10)* 8 *Markowitz M, et al . J Acquir Immune Defic Syndr 2006;43:509-515
Slide 9: Preliminary Safety Results
Preliminary Safety Results No serious adverse events No clinically significant laboratory abnormalities No discontinuations No typical NNRTI side effects: No abnormal dreams No drug-related rash No ECG-related adverse events RDEA806 (n=14) RDEA806 (n=14) Placebo (n=4) Placebo (n=4) n (%) n (%) Patie
Slide 10: Tablet Size Comparisons with Marketed Products
Tablet Size Comparisons with Marketed Products RDEA806 EC Tablet 200 mg SUSTIVA(r) 600 mg INTELENCE(tm) 100 mg 80% Drug 50% Drug 12.5% Drug RDEA806 EC Tablet 200 mg ATRIPLA(tm) 600/200/300 mg SUSTIVA(r) 600 mg INTELENCE(tm) 100 mg 80% Drug 67% Drug 50% Drug 12.5% Drug 10
Slide 11: Study RDEA806-202 Naive Dose Response Study
Study RDEA806-202 Naive Dose Response Study Study Start 3Q08 Primary Endpoint Proportion of patients with Plasma VL < 50 copies/mL Secondary Endpoints VL decay rate, CD4 and CD8 changes, PK, PK/PD, safety, tolerability, genotypic and phenotypic resistance Location International Study Population Male
Slide 12: RDEA427 Broad Spectrum Activity Against NNRTI-Resistant Viruses
12 RDEA427 has Broad Spectrum Activity Against the Most Prevalent NNRTI-Resistant Viruses 40% human serum Different structural class than RDEA806 Broad spectrum coverage of resistant strains
Slide 13: RDEA427 Phase 1 Micro-dose Study
RDEA427 Phase 0 Micro-dose Study Study No. Brief title RDEA900-001 NNRTI Exploratory IV Micro-dose Study 1^ Endpoint Pharmacokinetics of parent and metabolites using accelerator mass spectrometry (AMS) technology 2^ Endpoints None Location/# Sites UK/ 1 site Study Population Male Healthy volunteers
Slide 14: RDEA427 and Active Metabolite Long Plasma Half-lives
RDEA427 and Active Metabolite have Long Plasma Half-lives in Humans Time (hr) 10 100 1000 10000 0 10 20 30 40 50 60 70 80 14C RDEA427 Predominately active metabolite Mean t1/2 = 80.6 hr RDEA427 Mean t1/2 = 40.4 hr 14
Slide 15: Gout Unmet Medical Need
Gout Unmet Medical Need About the Indication Painful and debilitating disease Inflammation Disfiguring nodules (tophi) Attacks of severe pain (flares) Kidney damage (nephropathy) Caused by abnormally elevated levels of uric acid Increasing incidence and severity in U.S. (3-5M) Early onset, especiall
Slide 16: Urate Handling in the Nephron
~99% Reabsorption Secretion (~50%) Reabsorption (~10% fine tuning) Excretion: Normally ~10-12% of Filtered Load ~100% of uric acid is initially filtered through glomerular filtration URAT1 Enomoto; Urat1 identification in Nature May2002 D Levinson & L Sorensen; Renal Handling of Uric Acid Proximal T
Slide 17: RDEA594 Believed Responsible for Uric Acid Lowering
<99% Reabsorption Secretion (~50%) Reabsorption (~10% fine tuning) Increased Excretion ~100% of uric acid is initially filtered through glomerular filtration RDEA594, a RDEA806 Metabolite, is Believed to be Responsible for Uric Acid Lowering URAT1 Enomoto; Urat1 identification in Nature May2002 D Le
Slide 18: RDEA806 Significantly Reduced Serum Uric Acid in MAD Study
RDEA806 Significantly Reduced Serum Uric Acid in Phase 1 MAD Study 1 0.5 0 - -0.5 - -1 - -1.5 - -2 - -2.5 Day 0 Day 3 Day 7 Day 10/14 Follow-up Change in SUA (mg/dL) Treatment Day Placebo 500 mg bid 400 mg MR bid 300 mg bid - -3 * * * * * * * * * * p<0.001 18
Slide 19: Correlation Between Reduction and Baseline Serum Uric Acid
Significant Correlation Between Reduction and Baseline Serum Uric Acid Values Last Day of Dosing Change in SUA (mg/dL) Baseline Serum Uric Acid (mg/dL) 0.00 - -0.50 - -1.00 - -1.50 - -2.00 - -2.50 - -3.00 - -3.50 0.00 1.00 2.00 3.00 4.00 - -4.00 5.00 6.00 7.00 8.00 p=0.004 SUA > 6.8 mg/dL = hyperuri
Slide 20: Profile of RDEA594
Profile of RDEA594 Inhibits the URAT1 renal transporter, without significant antiviral activity Reduction in uric acid observed in Phase 1 and Phase 2a studies correlated with RDEA594 plasma concentrations Is a metabolite of RDEA806 in man and most of the animal species used in toxicology studies Hi
Slide 21: Next Steps in Gout
Next Steps in Gout Initiate small Phase 2 study with RDEA806 in 1H08 to demonstrate activity in target patient population: Patients with hyperuricemia and a history of gout Initiate Phase 1 study with RDEA594 in 2H08 All further gout studies will be conducted with RDEA594 Continue chemistry efforts
Slide 22: Competitive Landscape
Competitive Landscape Allopurinol 40 year old generic xanthine oxidase inhibitor, with limited efficacy and safety issues Febuxostat (TAP) 2nd generation xanthine oxidase inhibitor (more specific than allopurinol) Still in Phase 3 in the US due to safety concerns (has been associated with serious ca
Slide 23: The Age of Targeted Cancer Treatments
The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) XL518 (Ph 1) RDEA119 (Ph 1)* RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 23 *Only MEK inhibitor in clinic witho
Slide 24: RDEA119 is Potent, Highly Specific MEK Inhibitor
RDEA119 is Potent, Highly Specific MEK Inhibitor MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK
Slide 25: RDEA119 and RDEA436 have Low Brain Exposure
25 PD325901 RDEA436 RDEA119 RDEA119 and RDEA436 have Low Brain Exposure tumor lung brain % Inhibition of pERK Single 10 mg/kg dose of MEK inhibitor
Slide 26: RDEA119 Inhibits Tumor Volume
RDEA119 Inhibits Tumor Volume 0 10 20 30 40 Tumor volume (mm3) Days Vehicle RDEA119 25mg/kg RDEA119 50mg/kg RDEA119 100mg/kg 1200 1000 800 600 400 200 0 Dosing Period Preclinical colon cancer Xenograft model 26
Slide 27: Phase 1 Advanced Cancer Study Design
Study RDEA119 Primary Endpoint Safety, tolerability, PK Secondary Endpoints Pharmacodynamic (PD) measures: pERK, Ki67, Nras, Kras and Braf mutations; Antitumor activity by CT scan Location Von Hoff (Arizona), Weekes (UCHSC), Adjei (Roswell Park) Study Population Advanced cancer patients, all-comers
Slide 28: RDEA119 Plasma Levels in Cancer Patients
28 28 Target plasma levels for optimal efficacy from xenograft results RDEA119 Plasma Levels Following Single Oral Doses in Cancer Patients T1/2 = 16-26 hours Pharmacologically Active Range
Slide 29: RDEA119 Inhibits Cytokine Production in Whole Human Blood
RDEA119 Inhibits Cytokine Production in Ex Vivo Stimulated Whole Human Blood Whole human blood treated with 12-O-tetradecanoylphorbol-13- acetate (TPA) in presence of RDEA119 for 24h at 37^C - 5% CO2 29
Slide 30: Animal Models of Inflammatory Disease
Preclinical models of inflammation and arthritis where RDEA119 has demonstrated activity: Rat paw edema model Monosodium urate-Induced inflammatory cytokine production in human THP-1 Cells Collagen-induced arthritis in mice and rats (2008 EULAR) Adjuvant induced Arthritis (2008 EULAR) Pristane-induc
Slide 31: RDEA119 Phase 1 PK/PD Inflammation Biomarker Study
RDEA119 Phase 1 PK/PD Inflammation Biomarker Study 31 Study No. Brief title RDEA119-102 Ascending Dose - Food Effect Biomarker Study 1^ Endpoint Safety and Tolerability 2^ Endpoints PK, PD (pERK, TNF^, IL-6, and IL-1^), food effect Location/# Sites US/ 1 site Study Population Male and females of non
Slide 32: Financial Position Summary
Financial Position Summary Statement of Operations (In thousands, except per share data) Three Months Ended March 31, 2008 Revenue Operating expenses Interest and other income $260 $13,377 $742 NET LOSS $(12,375) NET LOSS PER SHARE $(0.93) 14.8 million common shares outstanding We expect to use $45-
Slide 33: Near-Term Anticipated Milestones
Near-Term Anticipated Milestones Drug Candidate Event Date HIV HIV HIV RDEA427 (2nd Gen NNRTI) FIH micro-dosing / human PK data 1Q08 ? RDEA806 Phase 2a results (PoC) 1Q08 ? RDEA806 Phase 2b start 3Q08 RDEA427 Phase 1 start 2H08 Gout Gout Gout RDEA806 Phase 2 start 2Q08 RDEA594 Phase 1 start 2H08 RDE
Slide 34: ) Biosciences”
) Biosciences” Designing Solutions for Serious Diseases NASDAQ: RDEA